Generic and specialty pharmaceutical company Mylan Pharmaceuticals has introduced a portfolio of women's healthcare products in India, expanding its product base in the country. Consisting of eight products initially, the portfolio is ...
Tags: Women's Care Products, Medicine
The US Food and Drug Administration (FDA) has given its clearance to Amgen's XGEVA (denosumab) to treat adult or skeletally mature patients suffering from giant cell tumor of bone (GCTB). Approved after conducting a priority review, XGEVA ...
Tags: Amgen's XGEVA, Medicine
Eisai has announced the availability of Belviq (lorcaserin HCl) CIV tablets in the US, which is designed for chronic weight management in adults who are overweight with a comorbidity or obesity. Indicated for people with body mass ...
Tags: Eisai, Weight Management Therapy
Takeda Pharmaceutical Company, AMAG Pharmaceuticals' European commercial partner, has submitted a type-II variation to the European Medicines Agency (EMA) for label expansion of Rienso (ferumoxytol). The approval will allow the use of ...
Tags: Takeda, EMA Approval
The US Patent and Trademark Office (USPTO) has granted a patent to GenSpera for the activation of peptide prodrugs by HK2, which is an enzyme secreted by prostate cancer cells. Composition of a series of prodrugs activated by HK2 enzyme ...
Tags: Peptide Prodrugs, Medicine
Daiichi Sankyo Company has filed a supplemental new drug application for extended indication of anticancer agent Topotecin intravenous drip infusion 40mg, 100mg with the Japan's Ministry of Health, Labor and Welfare. Topotecin intravenous ...
Johnson & Johnson's Pharmaceuticals unit Janssen is planning to submit more than 10 new products for regulatory approval and extend the brand pipeline of 25 existing drugs by 2017. The late stage products to be submitted for approval ...
Tags: Johnson&Johnson, New Drugs
R-Tech Ueno has begun enrolling patients with severe dry eye in Phase I/II study of recombinant human serum albumin-containing ophthalmic solution (development code: RU-101) in US. The two-stage trial is performed as a double masking test ...
Tags: R-Tech, Dry Eye Study
H. Lundbeck has introduced the first approved medication reducing alcohol consumption in alcohol dependent patients in Norway, Finland, Poland and the Baltic markets. Additional launches in other European countries are expected to follow ...
Tags: Lundbeck, Baltic Markets
Gurgaon, Haryana, India, Republic of (Free-Press-Release.com) April 3, 2013 -- One of the best accident insurance plans in India is IPA, Individual Personal Accident Insurance Policy. The plan is available in two variants to cater t the ...
Tags: Complete Protection, Individual Accident Health Insurance
Eisai's subsidiary Eisai Laboratorios has submitted a marketing authorization application (MAA) for Belviq (lorcaserin HCl) with the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico. Arena Pharmaceuticals's ...
Tags: Eisai, Mexican Marketing, Belviq
The Indian Supreme Court has rejected Novartis' patent application for its anti-cancer drug Glivec (imatinib mesylate) saying that “application for patent on the beta-crystalline salt does not meet any standard of novelty or ...
Tags: Indian Apex, Novartis'Patent Plea, Glivec
TransTech Pharma has received FDA fast track designation for new small-molecule chemical compound TTP488, for the treatment of Alzheimer's disease. TTP488 prevents interaction of a material found in the Alzheimer's patients cells, ...
Tags: Transtech Alzheimer, FDA, Medicine
Q. I am 68 and have only Medicare Part A. My sole source of income is $1,062 a month from Social Security. I'm in good health but concerned about future medical needs. Are there any plans for lower-income people? A.Yes, and it's a shame ...
Tags: Social Security, health, medical needs, healthcare
Daiichi Sankyo and Amplimmune have collaborated to develop AMP-110 therapeutic protein for the treatment of autoimmune diseases. The companies expect to commence Phase 1 study of the AMP-110 immune modulation therapy, which targets ...
Tags: Daiichi Sankyo, Amplimmune, therapeutic protein, autoimmune diseases